NCT04522323 - A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

September 26, 2025

Study Completion Date

September 26, 2025

Conditions

Advanced Renal Cell Carcinoma

Interventions

BIOLOGICAL

MEDI5752

DRUG

Axitinib

INLYTA

DRUG

Lenvatinib

LENVIMA

Trial Locations (20)

2298

Research Site, Waratah

3199

Research Site, Frankston

10065

Research Site, New York

14004

Research Site, Córdoba

17033

Research Site, Hershey

20007

Research Site, Washington D.C.

28040

Research Site, Madrid

28041

Research Site, Madrid

33908

Research Site, Fort Myers

37232

Research Site, Nashville

41013

Research Site, Seville

44195

Research Site, Cleveland

46009

Research Site, Valencia

63156

Research Site, St Louis

94805

Research Site, Villejuif

08003

Research Site, Barcelona

08025

Research Site, Barcelona

08035

Research Site, Barcelona

08908

Research Site, Barcelona

08208

Research Site, Sabadell